Bristol-Myers Squibb Company (NYSE:BMY) saw a downside of -0.51% to close Tuesday at $60.16 after subtracting -$0.31 on the day. The 5-day average trading volume is 9,742,720 shares of the company’s common stock. It has gained $62.33 in the past week and touched a new high 1 time within the past 5 days. An average of 9,807,195 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 8,908,446.
BMY’s 1-month performance is -3.71% or -$2.49 on its low of $59.71 reached on 08/08/23. The company’s shares have touched a 52-week low of $60.05 and high of $81.43, with the stock’s rally to the 52-week high happening on 02/06/23. YTD, BMY has lost -16.39% or -$11.79 and has reached a new high 9 times. However, the current price is down -26.13% from the 52-week high price.
Insider Transactions
BMY stock investors last saw insider trading activity on Aug 03.Plenge Robert M (EVP, Chief Research Officer) most recently sold 732 shares at $61.14 per share on Aug 03. This transaction cost the insider $44,754. EVP & President, Research, VESSEY RUPERT, sold 50,385 shares at a price of $67.06 on May 03. Then, on Feb 06, Board Chair and CEO Caforio Giovanni sold 240,000 shares at a price of $74.65 per share. This transaction amounted to $17,916,000.
Valuation Metrics
BMY stock has a beta of 0.41. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.82 while the price-to-book (PB) in the most recent quarter is 3.94, with the price to cash flow ratio at 21.10.
Bristol-Myers Squibb Company’s quick ratio for the period ended June 29 was 1.30, with the current ratio over the same period at 1.40. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.08, while the total debt to equity was 1.18.. In terms of profitability, the gross margin trailing 12 months is 77.10%. The trailing 12-month EBITDA margin is 42.37% while for the period ending June 29, Bristol-Myers Squibb Company’s operating margin was 22.00%. The firm’s gross profit as reported stood at $36.02 billion against revenue of $46.16 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Bristol-Myers Squibb Company’s cash and short-term investments amounted to $358.0 million against total debt of $39.21 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 31.45% to $2.07 billion, while revenue of $2.26 billion was -9.12% off the previous quarter. Analysts expected BMY to announce $1.8 per share in earnings in its latest quarter, but it posted $1.59, representing a -11.70% surprise. EBITDA for the quarter stood at more than $4.29 billion. BMY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 61.46 billion, with total debt at $39.21 billion. Shareholders hold equity totaling $2.09 billion.
Let’s look briefly at Bristol-Myers Squibb Company (BMY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 31.27% to suggest the stock is trending Neutral, with historical volatility in this time period at 24.43%.
The stock’s 5-day moving average is $60.82, reflecting a -2.23% or -$1.37 change from its current price. BMY is currently trading -4.19% above its 20-day SMA, -10.85% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -6.82% and SMA200 by-15.43%.
Stochastic %K and %D was 8.03% and 13.86% and the average true range (ATR) pointed at 1.17. The RSI (14) points at 34.33%, while the 14-day stochastic is at 7.94% with the period’s ATR at 1.15. The stock’s 9-day MACD Oscillator is pointing at -0.73 and -1.79 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Bristol-Myers Squibb Company (NYSE: BMY), HSBC Securities launched coverage with a Reduce rating. Analysts offering their rating for BMY stock have a consensus rating for the stock as Overweight. Currently, 2 brokerage advisors rate BMY as a “sell,”, while 12 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 10 have offered a “buy” rating.
What is BMY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $56.00 and a high of $90.00, with their median price target at $74.50. Looking at these predictions, the average price target given by analysts is for Bristol-Myers Squibb Company (BMY) stock is $73.09.
